Experimental water intoxication induced by dDAVP in rat, and its prevention with the vasopressin antagonist d(CH2)5Tyr(Et)VAVP.
A new rat model of the Schwartz--Bartter syndrome was created by the administration of 1-deamino-8-D-arginine vasopressin together with a forced water intake. The treatment led to water retention, hypernatriuria, marked hyponatraemia (in 4-5 days) and severe cerebral oedema. These changes could be prevented by the simultaneous administration of [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid)- 2-o-ethyltyrosine-4-valine] arginine vasopressin. The observations indicate that this vasopressin antagonist analogue might be of use in the future as an effective drug against the Schwartz--Bartter syndrome.
D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003894:Deamino Arginine Vasopressin; D004195:Disease Models, Animal; D007177:Inappropriate ADH Syndrome / Q000517:prevention & control*; D008297:Male; D051381:Rats; D014667:Vasopressins / Q000037:antagonists & inhibitors*; D014869:Water Intoxication / Q000517:prevention & control*
D014667:Vasopressins; D001127:Arginine Vasopressin; C028884:1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(O-ethyl-Tyr)-4-Val-arginine vasopressin; D003894:Deamino Arginine Vasopressin